Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015219 | PMC |
| http://dx.doi.org/10.1136/openhrt-2024-002659 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiomics approach to evaluating personalized biomarkers of allergen immunotherapy.
J Allergy Clin Immunol
September 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom; Frankland and Kay Allergy Centre, UK NIHR Imperial Biomedical Research Centre, United Kingdom.
Recent advancements in genomics and "omic" technologies have ushered in a transformative era referred to as personalized or precision medicine. This innovative approach considers the unique genetic profiles of individuals, along with a range of variability factors, to devise tailored disease treatments and prevention strategies that cater to the distinct needs of each patient. Although the terms personalized medicine and precision medicine are frequently utilized interchangeably, it is essential to delineate the subtle distinctions between them.
View Article and Find Full Text PDFReal-World Adherence and Persistence of Upfront Therapy in Patients with Pulmonary Arterial Hypertension in the United States.
Pulm Ther
September 2025
Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA.
Introduction: Pulmonary arterial hypertension (PAH) is a rare, progressive disease resulting from elevated pulmonary arterial pressure leading to right ventricular failure and death. Optimal adherence and persistence to medical therapy are necessary to improve outcomes. The objective of this study was to characterize adherence and persistence to first-line PAH therapies in patients newly initiating treatment.
View Article and Find Full Text PDFObesity and Atrial Fibrillation: From Mechanisms to Treatment.
Heart Lung Circ
September 2025
Centre for Heart Rhythm Disorders, The University of Adelaide, Royal Adelaide Hospital and South Australian Health & Medical Research Institute, Adelaide, SA, Australia. Electronic address:
By 2050, it is projected that 3.8 billion people worldwide will be overweight or obese. Alongside this growing burden of obesity is a parallel rise in the incidence and prevalence of atrial fibrillation (AF).
View Article and Find Full Text PDFA new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies.
ESC Heart Fail
September 2025
French Referral Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute, Amyloidosis Mondor Network, Henri-Mondor Teaching Hospital, AP-HP, Creteil, France.
Objectives: Currently, there are two prognosis staging systems validated for transthyretin amyloidosis (ATTR). We sought to develop a new staging system dedicated to hereditary transthyretin amyloidosis (ATTRv) patients on specific treatments.
Methods And Results: A total of 258 patients diagnosed with ATTRv from two cardiac amyloidosis reference centres in France and Romania were stratified into three disease stages based on NT-proBNP, estimated glomerular filtration rate (eGFR) and global longitudinal strain (GLS).
Population Pharmacokinetic Models of Ampicillin-Sulbactam Among Adult Patients with Infectious Diseases: A Systematic Review.
Ther Drug Monit
September 2025
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia.
Background: Ampicillin-sulbactam is the first-line treatment for pneumonia, aspiration pneumonia, and infections caused by Acinetobacter baumannii. Several population pharmacokinetic (PK) studies have evaluated the intravenous administration of ampicillin-sulbactam in adults. This systematic review aimed to compare published PK models and identify covariates influencing ampicillin-sulbactam PKs.
View Article and Find Full Text PDF